Resmed Stock Price, News & Analysis

ResMed has announced the promotion of Lucile Blaise to President of Sleep & Respiratory Care, effective July 1, 2022. Blaise, with over 25 years in the medtech industry, previously served as Vice President for Western Europe. She has been influential in establishing payer market access for digital health in France and Belgium and advocates for data privacy and real-world evidence in healthcare. CEO Mick Farrell praised her commitment to patient-centric care and innovative leadership, highlighting her vital role in improving treatments for chronic diseases.

ResMed has announced its acquisition of MEDIFOX DAN, a leader in out-of-hospital software solutions in Germany, for approximately US$1 billion. This acquisition enhances ResMed's position as a significant U.S. provider of SaaS solutions, extending its offerings into outpatient therapy within Germany. MEDIFOX DAN's software solutions are crucial for care providers, and the transaction is expected to be accretive to ResMed's non-GAAP diluted earnings per share. The deal is anticipated to close by the end of December 2022, pending regulatory approvals.

ResMed (NYSE: RMD) CEO Mick Farrell is set to participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 14, 2022, at approximately 1:20 p.m. PDT. This event will take place at the Terranea Resort in Rancho Palos Verdes, California. Interested parties can access a live webcast and a replay of the event via ResMed’s investor relations website, available for 12 hours post-event until June 14, 2023. ResMed focuses on innovative solutions for chronic disease management and aims to improve quality of life while reducing healthcare costs globally.

ResMed (NYSE: RMD) announced that Rob Douglas, its president and COO, will present at the William Blair Growth Stock Conference on June 8, 2022, at 9:20 a.m. CDT. The event will take place at the Loews Chicago Hotel, and investors can access more information and a live webcast through ResMed's investor site. A replay will be available approximately 12 hours after the event until September 6, 2022. ResMed focuses on innovative health solutions for chronic diseases, aiming to improve healthcare quality and reduce costs globally.

ResMed (NYSE: RMD) announced that CEO Mick Farrell will participate in a fireside chat at the Bernstein Strategic Decisions Conference on June 1, 2022, at 1:30 p.m. EDT in New York City. This event will provide insights into ResMed's strategies in healthcare innovation. A live webcast will be available on the company's investor relations website, with a replay accessible for one year after the event, until June 1, 2023. ResMed continues to be a leader in digital health technologies aimed at improving the quality of life for patients with chronic diseases.

ResMed's recent study highlights that sleep apnea patients can experience significant health benefits from just 2-3 hours of nightly PAP (positive airway pressure) usage. An analysis of 180,000 users found that each additional hour of PAP use reduces hospitalizations by 5% and emergency room visits by 4.4%. The study suggests that health systems should adapt their guidelines, as benefits extend up to 7 hours of use. Currently, Medicare requires a 4-hour minimum for adherence, which may hinder patient care. The study aims to reshape how healthcare professionals prescribe PAP therapy.

ResMed (NYSE: RMD) has announced the immediate departure of Jim Hollingshead, who served as the President of Sleep and Respiratory Care, after 12 years with the company. Rob Douglas has been appointed as interim President. CEO Mick Farrell acknowledged Hollingshead’s significant contributions to ResMed, particularly in digital health transformation. The transition aims to maintain strong leadership as the company positions itself for continued growth into 2025 and beyond.

ResMed reported a 12% year-over-year revenue increase to $864.5 million in Q3 2022, with a 14% rise on a constant currency basis. Operating profit grew by 5%, and diluted EPS reached $1.22. Despite a contraction in gross margins due to higher costs, strong demand in the sleep and respiratory care sector contributed to sales growth. The company faces supply chain challenges but maintains a positive outlook for its long-term strategy, aiming to impact 250 million lives by 2025.

ResMed (NYSE: RMD) announced that CFO Brett Sandercock will present at the Macquarie Australia Conference on May 3, 2022, starting at 8:45 a.m. Australian Eastern Standard Time. The presentation will be available via video webcast, with a replay accessible 24 hours after the live event until August 1, 2022. ResMed specializes in digital health technologies and cloud-connected medical devices aimed at improving the quality of life for individuals suffering from chronic diseases such as sleep apnea and COPD in over 140 countries.